Methylation-Mediated Silencing of Protein Kinase C Zeta Induces Apoptosis Avoidance through ATM/CHK2 Inactivation in Dedifferentiated Chondrosarcoma

Researchers identified genes downregulated in dedifferentiated chondrosarcoma vs. conventional chondrosarcoma due to DNA methylation using in silico analysis.
[British Journal of Cancer]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

The DNMT1 Inhibitor GSK-3484862 Mediates Global Demethylation in Murine Embryonic Stem Cells

Researchers determined whether GSK-3484862 can induce demethylation more effectively than 5-azanucleosides. They determined the cytotoxicity and optimal concentration of GSK-3484862 by treating wild-type or Dnmt1/3a/3b triple knockout mESC with different concentrations of the compound, which was obtained from two commercial sources.
[Epigenetics & Chromatin]
[zotpress userid=” items=’EEEEEEEE’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Targeting DNMT1 by Demethylating Agent OR-2100 Increases Tyrosine Kinase Inhibitors-Sensitivity and Depletes Leukemic Stem Cells in Chronic Myeloid Leukemia

OR21 exhibited anti-tumor effects as a monotherapy, and in combination therapy it increased tyrosine kinase inhibitors -induced apoptosis and induction of tumor suppressor genes including PTPN6 encoding SHP-1 in chronic myeloid leukemia cells.
[Cancer Letters]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer

Scientists suggested that DNA methylation pathway is deregulated after enzalutamide resistance onset and that targeting DNA methyltransferases restored the sensitivity to enzalutamide in prostate cancer cells.
[Molecular Cancer therapeutics]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Discovery of a First-in-Class Reversible DNMT1-Selective Inhibitor with Improved Tolerability and Efficacy in Acute Myeloid Leukemia

Due to improved in vivo tolerability compared with decitabine, GSK3685032 yielded superior tumor regression and survival mouse models of acute myeloid leukemia.
[Nature Cancer]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Low-Dose Decitabine Modulates T-Cell Homeostasis and Restores Immune Tolerance in Immune Thrombocytopenia

Scientists analyzed the effect of decitabine on T-cell subpopulations in immune thrombocytopenia in vitro and in vivo. They found that low-dose decitabine promoted the generation and differentiation of regulatory T cells and augmented their immunosuppressive function.
[Blood]
[zotpress userid=’7992332′ items=’ZMJ9X5TD’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

Bio-Path Holdings, Inc. announced that the US FDA has reviewed and cleared the Investigational New Drug application for BP1002, the company’s second drug candidate, for an initial Phase I/Ib clinical trial that will evaluate the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients.
[Bio-Path Holdings, Inc.]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

In Vitro and In Vivo Induction of Fetal Hemoglobin with a Reversible and Selective DNMT1 Inhibitor

The authors reported the discovery of a novel class of orally bioavailable DNA methyltransferase (DNMT1)-selective inhibitors as exemplified by GSK3482364.
[Haematologica]
[zotpress userid=’7992332′ items=’UDZ27FZ2′ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Increasing Recognition and Emerging Therapies Argue for Dedicated Clinical Trials in Chronic Myelomonocytic Leukemia

Investigators discuss recent therapeutic advances and innovative treatment strategies in chronic myelomonocytic leukemia (CMML), including global and molecularly targeted approaches, and discuss what may help to make progress in the design of rationally derived and disease-modifying therapies for CMML.
[Leukemia]
[zotpress userid=’7992332′ items=’Z5DCGQ49′ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

AbbVie Receives European Commission Approval of VENCLYXTO® (Venetoclax) in Combination with a Hypomethylating Agent for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

AbbVie, Inc. announced that the European Commission has approved VENCLYXTO® in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
[AbbVie, Inc.]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Hypomethylating Agents (HMA) for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes: Mechanisms of Resistance and Novel HMA-Based Therapies

The authors provide insights into the mode of action of HMA, mechanisms of resistance to this treatment, and strategies to overcome HMA resistance including next-generation HMA and HMA-based combination therapies.
[Leukemia]
[zotpress userid=’6445218′ items=’AUZWLMDV’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share
Share